Technical Analysis for URGN - UroGen Pharma Ltd.

Grade Last Price % Change Price Change
grade C 48.75 2.52% 1.20
URGN closed up 2.52 percent on Thursday, September 20, 2018, on 1.2 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical URGN trend table...

Date Alert Name Type % Chg
Sep 20 MACD Bullish Centerline Cross Bullish 0.00%
Sep 20 Up 3 Days in a Row Strength 0.00%
Sep 19 Crossed Above 20 DMA Bullish 2.52%
Sep 19 Crossed Above 50 DMA Bullish 2.52%
Sep 19 Expansion Pivot Buy Setup Bullish Swing Setup 2.52%
Sep 18 20 DMA Resistance Bearish 8.24%
Sep 18 50 DMA Resistance Bearish 8.24%
Sep 18 Outside Day Range Expansion 8.24%
Sep 17 Fell Below 20 DMA Bearish 8.31%
Sep 17 Fell Below 50 DMA Bearish 8.31%

Older signals for URGN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
UroGen Pharma Ltd. (UroGen) is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). Its other clinical-stage drug candidate includes Vesimune and BotuGel. Vesimune is a formulation of the toll-like receptor7 (TLR7) agonist Imiquimod for local intravesical delivery for the treatment of Carcinoma In-Situ. BotuGel is an intravesical sustained release formulation of botulinum toxin for Overactive Bladder (OAB) and Interstitial Cystitis (IC). UroGen has developed two platform technologies: RTGel and Immunotherapy.
Is URGN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 69.57
52 Week Low 25.56
Average Volume 69,340
200-Day Moving Average 50.5177
50-Day Moving Average 45.677
20-Day Moving Average 45.8315
10-Day Moving Average 45.238
Average True Range 2.3242
ADX 23.64
+DI 25.0578
-DI 20.0991
Chandelier Exit (Long, 3 ATRs ) 42.3674
Chandelier Exit (Short, 3 ATRs ) 49.1126
Upper Bollinger Band 49.58
Lower Bollinger Band 42.083
Percent B (%b) 0.89
BandWidth 16.357745
MACD Line 0.1863
MACD Signal Line -0.1931
MACD Histogram 0.3793
Fundamentals Value
Market Cap 634.2 Million
Num Shares 13 Million
EPS -1.67
Price-to-Earnings (P/E) Ratio -29.19
Price-to-Sales 20.42
Price-to-Book 4.84
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 52.13
Resistance 3 (R3) 51.83 50.41 51.56
Resistance 2 (R2) 50.41 49.55 50.56 51.37
Resistance 1 (R1) 49.58 49.02 50.00 49.88 51.19
Pivot Point 48.16 48.16 48.37 48.31 48.16
Support 1 (S1) 47.33 47.30 47.75 47.63 46.31
Support 2 (S2) 45.91 46.77 46.06 46.13
Support 3 (S3) 45.08 45.91 45.94
Support 4 (S4) 45.38